NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring clinical-stage gene therapy company Genprex Inc. (GNPX), a client of NNW developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM), immunogene therapy for non-small cell lung cancer (NSCLC).
To view the full publication, titled “Making Profits, Saving Lives with Gene Therapy,” visit: http://nnw.fm/Y0ZqH
Gene therapy isn’t exactly new. For years, companies such as Genprex Inc. (GNPX) have been working on improvements to the technology and new ways to apply it in improving and saving lives. The highest profile work has been done in tackling cancer, an area in which Genprex specializes. The difficulty of treating cancer, combined with its origin in cell growth gone bad, makes gene therapy a natural fit for this area. But plenty of other uses have also been explored over the past three decades.
If gene therapy has been around for this long, why is now such an ideal time to invest?
One reason is that the industry has seen a series of mergers and acquisitions. Small-cap biotech company Spark Therapeutics, which specializes in gene therapy, was recently bought up by Roche for $4.8 billion, offering Spark investors a likely gain of 190 percent for this year. MeiraGTx Holdings, another small-cap gene therapy company, achieved an $80 million private placement, with Johnson & Johnson as its lead investor, pushing its shares up 67 percent so far this year. These and other moves show the interest of big medical companies in gene therapy.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.